
The value of capability in allogeneic cell therapy: an interview with Andy Holt
Published on January 16, 2023
In this interview, we spoke to Andy about Cellistic’s recent acquisition of a GMP facility and how their newly increased capabilities will help them make a bigger difference in bringing iPSC-based allogeneic cell therapies to patients faster. Plus, Andy gave us a sneak peek into some of Cellistic’s upcoming projects and his predictions for how the iPSC landscape will evolve in the next five years.
